Session date: 
03/28/2022 - 12:00pm to 1:00pm

Title:   Disease Modifying Therapeutics in Dementia: Focus on Aducanumab 

Learning Objectives:    Upon conclusion of this activity, participants should be able to:

  • Describe the rationale for the use of aducanumab
  • Analyze the data regarding clinical efficacy and safety of aducanumab
  • Provide practical considerations for clinical use of aducanumab
  • Explore future treatment options in dementia

 

ATTENDANCE / CREDIT
Text the session code (provided only at the session) to 507-200-3010image within 48 hours of the live presentation to record attendance. All learners are encouraged to text attendance regardless of credit needs. This number is only used for receiving text messages related to tracking attendance. Additional tasks to obtain credit may be required based on the specific activity requirements and will be announced accordingly. Swiping your badge will not provide credit; that process is only applicable to meet GME requirements for Residents & Fellows.

TRANSCRIPT
Any credit or attendance awarded from this session will appear on your Transcript.

For disclosure information regarding Mayo Clinic School of Continuous Professional Development accreditation review committee member(s) and staff, please go here to review disclosures.

Presenter: 
Meredith Wicklund
Where did the idea for the course originate?: 
Arizona
Please login or register to take this course.
Where did the idea for the course originate?: 
Arizona